ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2531

Coronary periarteritis in IgG4-Related Disease

Georges El Hasbani1, Daniel Larson2, Matthew Koster1 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester

Meeting: ACR Convergence 2025

Keywords: Biologicals, Computed tomography (CT), glucocorticoids, Heart disease, IgG4 Related Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2524–2546) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: IgG4-related disease (IgG4-RD) is characterized by chronic inflammation and fibrosis, which can affect multiple organs, especially the pancreas, salivary glands, and retroperitoneum (1). It may lead to periaortitis, affecting up to 20% of patients, and in rare cases, coronary periarteritis, which can cause severe complications like myocardial infarction (2). This case series aims to explore the clinical and radiological features of coronary periarteritis in IgG4-RD and discuss complications and treatment options. 1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51.2. Katz G, Hedgire SH, Stone JR, Perez-Espina S, Fernandes A, Perugino CA, et al. IgG4-related disease as a variable-vessel vasculitis: A case series of 13 patients with medium-sized coronary artery involvement. Semin Arthritis Rheum. 2023;60:152184.

Methods: A review of the electronic health records was conducted using keywords related to IgG4-RD and coronary involvement. Out of 146 patients reviewed, 9 patients had confirmed IgG4-RD with coronary involvement. Data extracted included diagnosis date, serum IgG4 and C-reactive protein levels, imaging findings, cardiac complications, and treatment details.

Results: All 9 patients were male, with a mean age of 55.5 ± 5.7 years at diagnosis. The mean serum IgG-4 level was 738 ± 1280 mg/dL, while the mean C-reactive protein value was 39.9 ± 54.8 mg/L. The average time between diagnosis of IgG4-RD and coronary involvement was 2 years and 6 months. A tissue biopsy showed IgG4-positive plasma cells in all cases. Coronary artery involvement was primarily detected through CT angiography, showing thickening of vessel walls (Table) . The right coronary artery (RCA) was affected in 5 patients, the left anterior descending artery (LAD) in 4, and the left main coronary artery in 1. In 5 patients, the periarteritis involved the entire length of the coronary artery, and 1 patient had an aneurysm of the LAD. Regarding treatment, all patients received glucocorticoids, and 7 patients were additionally treated with rituximab (RTX). Two patients received RTX for induction only, while 4 patients had induction and maintenance RTX infusions. One patient developed ischemic heart disease, and one progressed to heart failure. Follow-up imaging showed partial or complete resolution of vessel thickening in 7 patients.

Conclusion: Coronary artery involvement in IgG4-RD is rare but significant, leading to periarteritis, and subsequently coronary aneurysm formation. The RCA and LAD appear to be most affected in this condition, with imaging techniques such as cardiac CT being effectively used as diagnostic tool. Rituximab has shown promising data in managing coronary involvement, though its use in this context remains limited, ultimately necessitating larger studies.

Supporting image 1Patient demographics and clinical features.

Supporting image 2CT cardiac demonstrating thickening of the wall of the right coronary artery. H&E, pelvic lymph node biopsy with plasmacytosis. IgG shows most plasma cells express IgG. IgG4 shows 30-40% of plasma cells are IgG4-postive, with over 100/hpf.


Disclosures: G. El Hasbani: None; D. Larson: None; M. Koster: Amgen, 2; K. Warrington: Bristol-Myers Squibb(BMS), 5, Sanofi, 2.

To cite this abstract in AMA style:

El Hasbani G, Larson D, Koster M, Warrington K. Coronary periarteritis in IgG4-Related Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/coronary-periarteritis-in-igg4-related-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/coronary-periarteritis-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology